78 reports of this reaction
1.3% of all SENNOSIDES A AND B reports
#16 most reported adverse reaction
HYPERHIDROSIS is the #16 most commonly reported adverse reaction for SENNOSIDES A AND B, manufactured by SDA Laboratories, Inc.. There are 78 FDA adverse event reports linking SENNOSIDES A AND B to HYPERHIDROSIS. This represents approximately 1.3% of all 5,780 adverse event reports for this drug.
Patients taking SENNOSIDES A AND B who experience hyperhidrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERHIDROSIS is a less commonly reported adverse event for SENNOSIDES A AND B, but still significant enough to appear in the safety profile.
In addition to hyperhidrosis, the following adverse reactions have been reported for SENNOSIDES A AND B:
The following drugs have also been linked to hyperhidrosis in FDA adverse event reports:
HYPERHIDROSIS has been reported as an adverse event in 78 FDA reports for SENNOSIDES A AND B. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERHIDROSIS accounts for approximately 1.3% of all adverse event reports for SENNOSIDES A AND B, making it a notable side effect.
If you experience hyperhidrosis while taking SENNOSIDES A AND B, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.